Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067347 · ClinicalTrials.gov registry record
A Global Study of the PETAL Consortium
A clinical trial of T-Cell and NK-Cell Neoplasm, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 13
- Study locations
NCT06067347: Recruiting study of T-Cell and NK-Cell Neoplasm, sponsored by Massachusetts General Hospital.
NCT06067347 is a study of T-Cell and NK-Cell Neoplasm that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 1,200 participants. The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06067347, a study of T-Cell and NK-Cell Neoplasm, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
Primary Outcome
Difference in overall survival (OS) in subjects with primary refractory versus relapsed mature T-cell and NK-cell neoplasms at the completion of 4 years.
Conditions Studied
Study Locations (13)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- City of Hope - Duarte
Colorado
- University of Colorado - Denver
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- OhioHealth - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- University of Virginia - Charlottesville
South Australia
- Royal Adelaide Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2028-01 |
What NCT06067347 shows while recruiting
NCT06067347 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with T-Cell and NK-Cell Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT06067347 lists 13 locations in 12 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06067347 about?
NCT06067347 is a clinical study titled "A Global Study of the PETAL Consortium". The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize th...
What is the current status of trial NCT06067347?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2024-01-05. Estimated completion is 2028-01.
What conditions does trial NCT06067347 study?
This clinical trial studies the following conditions: T-Cell and NK-Cell Neoplasm.
Who is sponsoring clinical trial NCT06067347?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06067347 being conducted?
This trial has 13 study locations across California, Colorado, Massachusetts, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI